A strong position in the global blood products industry makes CSL a defensive growth investment.
We are increasing our fair value estimate for narrow-moat CSL to AUD 137 per share after adjusting for recent currency movements, namely changing our Australian dollar/U.S. dollar exchange rate to 0.77 from 0.79. This follows the company’s recent R&D investor day in which CSL confirmed it will spend up to USD 550 million on phase III clinical trials of CSL112, its potential blockbuster breakthrough product candidate for preventing secondary heart attacks. CSL plans to commence a 17,400-patie...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.